Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)- camptothecin administered as a 72-hour continuous intravenous infusion

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 317-324

  Eder Jr , Joseph P ^a   Supko, Jeffrey G ^a   Lynch, Thomas ^a   Bryant, Margaret ^a   Vosburgh, Evan ^b   Shulman, Lawrence N ^a   Xu, Guangxin ^a   Kufe, Donald W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; GLUCOSE; MACROGOL 400; N,N DIMETHYLACETAMIDE; PHOSPHORIC ACID; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLOID; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0031937373     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cai, J. C., and Hutchinson, C. R. Camptothecin. In: A. Brossi (ed.). The Alkaloids, Vol. 21, pp. 101-137. Orlando, FL: Academic Press, 1993.
2. Suffness, M., and Cordell, G. A. Camptothecin. In: A. Brossi (ed.) The Alkaloids, vol. 21, pp. 73-89. Orlando, FL: Academic Press, 1993.
3. Wall, M. E., Wani, M. C., Natscke, S. M., and Nicholas, A. W. Plant antitumor agents 22. Isolation of 11 -hydroxycamptothecin from Camptotheca accuminata Decne: total synthesis and biologic activity. J. Med. Chem., 29: 1553-1555, 1986.
4. Wani, M., Nicolas, A., Manikumar, G., and Wall, M. E. Plant antitumor agents: 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J. Med. Chem., 30: 1774-1779, 1987.
5. Horowitz, S., and Horowitz, M. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res., 33: 2834-2836, 1973.
6. Hsiang, Y-H., Hertzberg, R., Hecht, S., and Liu, L. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 1473-1478, 1985.
7. Tsao, Y., Russo, A., Nyamuswa, N., Silber, R., and Liu, L. F. Interaction between replication forks and topoisomerase I-DNA cleavage complexes: studies in a cell-free SV-40 DNA replication system. Cancer Res., 53: 5908-5914, 1993.
8. Nitiss, J., and Wang, J. DNA topoisomerase targeting drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA, 85: 7501-7505, 1988.
9. Liu, L. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
10. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
11. Nicolas, A. W., Wani, M. C., Manikumar, G., Wall, M. E., Kohn, K. W., and Pommier, Y. Plant antitumor agents 29: synthesis and biologic activity of ring D and ring E modified analogues of camptothecin. J. Med. Chem., 33: 972-978, 1990.
12. Underberg, W. J. M., Goosen, R. M. J., Smith, B. R., and Beijnen, J. H. Equilibrium kinetics of the new antitumor compounds SK&F 104864-A in aqueous solution. J. Pharm. Biomed. Anal., 8: 681-683, 1990.
13. Beijnen, J. H., Smith, B. R., Keijer, W. J., Van Gijn, R., ten Bokkel Shuinink, W. W., Vlasveld, L. T., Rodenhuis, S., and Underberg, W. J. M. High performance liquid chromatographic analysis of the new antitumor agent SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
14. Supko, J. G., and Malspeis, L. Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J. Liq. Chromatogr., 15: 3261-3283, 1992.
15. Staubus, A. E., Rutherford, M., Snuffer, P., and Feller, D. Kinetics of ring opening of camptothecin analogues and topotecan in plasma and whole blood. Proc. Am. Assoc. Cancer Res., 33: 531, 1992.
16. Gottlieb, J., Guarin, A., Call, J. B., Oliviero, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC100880). Cancer Chemother. Rep., 54: 461-470, 1970.
17. Muggia, F., Creaven, P., Hansen, H., Cohen, M. H., and Selawry, O. S. Phase I trial of weekly and daily treatment with camptothecin (NSC100880): correlation with preclinical studies. Cancer Chemother. Rep., 56: 515-521, 1972.
18. Moertel, C., Schutt, A., Reitemeier, R., and Hahn, H. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56: 95-101, 1972.
19. Supko, J. G., and Malspeis, L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res., 53: 3062-3069, 1993.
20. Potmesil, M., Giovanella, B. C., Liu, L. F., Wall, M. E., Silber, R., Stehlin, J. S., Hsiang, Y. H., and Wani, M. C. Preclinical studies of DNA topoisomerase I targeted of 9-amino and 10,11-methylenedioxy camptothecins. In: M. Potmesil and K. W. Kohn (eds.). DNA Topoisomerases in Cancer, pp. 299-311. New York: Oxford University Press, 1991.
21. Giovanella, B., Stehlin, J., Wall, M., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
22. Chen, A., Yu, C., Potmesil, M., Wall, M. E, Wani, M. C., and Liu, L. F. Camptothecin overcomes MDR-1-mediated resistance in human KB carcinoma cells. Cancer Res., 51: 6039-6044, 1991.
23. Hendricks, C., Rowinsky, E., Grochow, L, Donehower, R. C., and Kaufmann, S. H. Effects of P-glycoprotein expression on accumulation and cytotoxicity of topotecan (SKF104864). Cancer Res., 52: 2268-2278, 1992.
24. Rubin, E., Wood, V., Bharti, A., Trites, D., Lynch, C., Hurwitz, S., Bartel, S., Levy, S., Rosowsky, A., Toppmeyer. D., and Kufe, D. A Phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res., 1: 269-276, 1995.
25. Dahut, W., Harold, N., Takimoto, C., Allegra, C., Chen, A., Hamilton, J. M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, W., and Grem, J. A Phase I and pharmacologie study of 9-aminocamptothecin given by 72 h infusion in adult cancer patients. J. Clin. Oncol., 14: 1230-1244, 1996.
26. Leventhal, B. G., and Wittes, R. E. Common Toxicity Criteria in Research Methods in Clinical Oncology. New York: Raven Press, 1988.
27. Takimoto, C. H., Klecker, R. W., Dahut, W. L., Yee, L. K., Strong, J. M., Allegra, C. J., and Grem, J. L. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B, 655: 97-104, 1994.
28. Gibaldi, M., and Perrier, D. Pharmacokinetics, pp. 84-109, 409-416. New York: Marcel Dekker, 1982.
29. Benet, L. Z. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J. Pharm. Sci., 61: 536-541, 1972.
30. Gabrielsson, J., and Weiner, D. Pharmacokinetic and Pharmacodynamic Data Analysis, pp. 9-40, 107-114. Stockholm: Swedish Pharmaceutical Press, 1994.
31. Takimoto, C. H., Dahut, W., Marino, M. T., Lieberman, R., Arbuck, S. G., Band, R. A., Chen, A. P., Hamilton, J. M., Cantilena, L., Alegra, C. J., and Gem, J. L. Pharmacodynamics and pharmacokinetics of a 72 hour infusion of 9-aminocamptothecin in adult cancer patients. J. Clin. Oncol., 15: 1492-1501, 1997.
32. Ansari, R. H., Masters, G. A., Hoffman, P. C., Hoehne, C., Critchlow, R., Sciortino, D., Kuglar, J. W., Ratain, M. J., Golomb, H. M., and Yokes, E. E. A Phase II trial of 9-aminocamptothecin in advanced nonsmall cell lung cancer. Proc. Am. Soc. Clin. Oncol., 15: 408, 1996.
33. Potmesil, M. Camptothecins. From bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
34. Wang, J. C. DNA Topoisomerases. Annu. Rev. Biochem., 65: 635-692, 1996.
35. Supko, J. G., Plowman, J., Dykes, D., and Zaharko, D. S. Relationship between the schedule dependence 9-amino-20(S)-camptothecin (AC; NSC603071) antitumor activity in mice and its plasma pharmacokinetics. Proc. Am. Assoc. Cancer Res., 33: 432, 1992.
36. Kudelka, A. P., Tresukosol, D., Edwards, C. L., Freedman, R. S., Levenback, C., Chanterawiroj, P., Gonzalez de Leon, C., Kim, E. E., Madden, T., Wallin, B., Hord, M., Verschraegen, C., Raber, M., and Kavanagh, J. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol., 14: 1552-1557, 1996.